DEF: Daxor Corporation Schedules 2025 Annual Stockholder Meeting to Elect Directors and Ratify Auditor

Daxor Corporation announced its Annual Meeting of Stockholders for June 24, 2025, to elect six directors and ratify the appointment of Bush & Associates, CPA as its independent registered public accounting firm for the fiscal year ending December 31, 2025.

Summary

• Daxor Corporation will hold its Annual Meeting of Stockholders on Tuesday, June 24, 2025, at 10:45 AM EDT, at the Nasdaq Stock Exchange offices in New York.
• The primary purposes of the meeting are to elect a board of six directors, each for a one-year term, and to ratify the appointment of Bush & Associates, CPA as the independent registered public accounting firm for the year ending December 31, 2025.
• The Board of Directors recommends a vote FOR ALL NOMINEES for directors and FOR the ratification of Bush & Associates, CPA.
• Stockholders of record at the close of business on May 19, 2025, are entitled to vote, with 4,962,245 shares of common stock outstanding as of that date.
• Daxor qualifies as a 'controlled company' under Nasdaq rules, as the Estate of Joseph Feldschuh, MD, controls over 50% of the company's voting power (51.5% beneficial ownership).
• Due to its 'controlled company' status, Daxor is exempt from certain Nasdaq corporate governance requirements, such as having independent nominating and compensation committees; the full Board handles these functions directly.
• The Audit Committee, consisting of independent directors Edward Feuer (Chairperson and financial expert), Joy Goudie, and Caleb DesRosiers, met 4 times in 2024.
• Officer compensation for the last completed fiscal year (FY2024) included: Michael Feldschuh ($101,002 cash/benefits + $400,050 in vested stock grants), Jonathan Feldschuh ($129,205 cash/benefits + $284,480 in vested stock grants), John Jefferies ($160,614 cash/benefits), and Robert J. Michel ($151,507 cash/benefits + $42,228 in vested stock grants).
• Non-interested directors received compensation for meeting attendance in 2024, including $1,000 for the annual meeting and $375 per dial-in Board meeting.
• The company changed its independent auditor for FY2024; Citrin Cooperman & Company, LLP resigned on November 1, 2024, and Bush & Associates CPA was appointed on December 3, 2024. No disagreements or reportable events were reported with the prior auditor.
• Audit fees for FY2024 were $85,100 (Bush & Associates CPA), compared to $109,250 (Citrin Cooperman LLP) for FY2023. Tax fees for FY2024 were $18,675 (Zelin & Associates CPA LLC).

Sentiment

Score: 5

Explanation: The document is a standard procedural proxy statement for an annual meeting, presenting factual information about corporate governance, director elections, and auditor ratification. It contains no positive or negative operational or financial news that would significantly sway sentiment, maintaining a neutral tone.

Positives

• The Audit Committee is composed entirely of independent directors, and includes a designated financial expert, aligning with strong oversight practices.
• The company reported no disagreements on accounting principles or practices, financial statement disclosure, or auditing scope and procedures with its previous independent auditor, Citrin Cooperman & Company, LLP, prior to their resignation.
• Board members demonstrated strong attendance in 2024, with each incumbent director attending at least 75% of the four Board meetings held.

Negatives

• As a 'controlled company,' Daxor is exempt from certain Nasdaq corporate governance requirements, such as having independent nominating and compensation committees, which could potentially lead to fewer protections for minority shareholders if the controlling stockholder's interests diverge from others.
• The Board directly handles director nominations and compensation considerations, rather than through independent committees, which is a deviation from best practices for corporate governance in many public companies.

Risks

• Corporate Governance: As a controlled company, the Estate of Joseph Feldschuh, MD, controls over 50% of the voting power, allowing Daxor to be exempt from certain Nasdaq corporate governance rules (e.g., independent nominating and compensation committees). This structure could lead to situations where the interests of the controlling stockholder differ from those of other stockholders, potentially reducing protections for minority shareholders.
• Risk Oversight Limitations: The Board acknowledges that it is not practicable or possible to identify all risks that may impact the Company or to develop procedures or controls designed to eliminate all such risk exposures.

Future Outlook

The document primarily outlines the agenda for the upcoming Annual Meeting, including the election of directors and the ratification of the independent auditor. It also mentions that management will report on the company's performance during 2024 at the meeting. No explicit forward-looking financial guidance or strategic outlook beyond these procedural matters is provided.

Management Comments

• "Our Board of Directors recommends a vote FOR ALL NOMINEES in Proposal 1, and FOR ratification of the appointment of Bush & Associates CPA, as the independent registered public accounting firm in Proposal 2."
• "The management of the Company is the responsibility of the Board."
• "We have determined that our leadership structure is appropriate given the size and structure of the Company."
• "The Board notes that it is not practicable or possible to identify all of the risks that may impact the Company or to develop procedures or controls that are designed to eliminate all such risk exposures, and that applicable securities law regulations do not contemplate that all such risks be identified and addressed, but that the Board carefully evaluates and addresses all material risks."

Industry Context

Daxor's status as a 'controlled company' is a significant aspect of its corporate governance structure. This allows it to be exempt from certain Nasdaq corporate governance requirements, such as having independent nominating and compensation committees. While legally permissible, this structure deviates from the governance practices of many widely-held public companies that typically adopt more independent board structures to enhance shareholder protections and align with broader industry best practices for corporate transparency and accountability.

Comparison to Industry Standards

• Daxor's corporate governance structure, specifically its exemption from certain Nasdaq listing standards due to its 'controlled company' status, deviates from the governance practices of many widely-held public companies that typically have independent nominating and compensation committees.
• The Board's direct responsibility for director nominations and compensation, rather than through independent committees, contrasts with the governance models of companies adhering to stricter independence requirements.
• The compensation structure for non-interested directors, involving fixed fees for meeting attendance ($1,000 for annual, $375 for dial-in), is a common practice, though the specific amounts may vary across companies.
• The audit committee's composition, with all members being independent and one designated as a financial expert, aligns with standard SEC and Nasdaq requirements for audit committees.

Management Changes

Corporate Governance

Related Party Transactions

• The Estate of Joseph Feldschuh, MD, is identified as a control person, beneficially owning 51.5% of the company's common stock.
• Michael Feldschuh (President and CEO) and Jonathan Feldschuh (Chief Scientific Officer) are identified as 'interested persons' and directors, and received significant stock grants in FY2024.

Stakeholder Impact

• Shareholders: Will participate in key corporate governance decisions, including the election of directors and ratification of the auditor. Minority shareholders may face reduced protections due to the company's 'controlled company' status.
• Employees: Key officers received compensation, including stock grants, which aligns their interests with the company's performance.
• Auditors: Bush & Associates, CPA is proposed for ratification, indicating their continued role in auditing the company's financial statements.

Next Steps

• Stockholders are urged to vote on the election of six directors and the ratification of Bush & Associates, CPA as the independent registered public accounting firm for the year ending December 31, 2025.
• Management will report on the company's performance during 2024 and respond to questions from stockholders at the Annual Meeting on June 24, 2025.
• Stockholders interested in presenting a proposal for consideration at the 2026 Annual Meeting must submit it to the company's President by February 21, 2026.

Key Dates

Recommendation

Keywords

SEC filing, proxy statement, DEF 14A, annual meeting, corporate governance, board of directors, auditor ratification, shareholder vote, controlled company, Daxor Corporation, executive compensation, audit committee, financial reporting